Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Completed 2Terminated 1Active not recruiting 1

Sponsor Class

NIH 1

Study Type

Interventional 1

Sponsor

Cancer Type

Sarcoma 1

Conditions

Neoplasms 2Neoplasm Metastasis 2Colorectal Neoplasms 2Uveal Melanoma 1Sarcoma 1Pancreatic Neoplasms 1Neurofibromatosis 2 1Myeloproliferative Disorders 1Multiple Myeloma 1Macular Degeneration 1Lung Neoplasms 1Leukemia, Myelomonocytic, Chronic 1Leukemia, Myeloid, Chronic, Atypical, BCR-ABL Negative 1Colorectal Cancer Metastatic 1Carcinoma, Non-Small-Cell Lung 1

Interventions

Doxorubicin 13Gemcitabine 10Cyclophosphamide 10pazopanib 8Filgrastim 8Radiotherapy 7Ifosfamide 7Cisplatin 7Irinotecan 6Docetaxel 6Radiation 5Granulocyte Colony-Stimulating Factor 5Etoposide 5Trabectedin 4Magnetic Resonance Spectroscopy 4Celecoxib 4Busulfan 4Bevacizumab 4Albumin-Bound Paclitaxel 4temsirolimus 3sargramostim 3pembrolizumab 3X-Rays 3Sirolimus 3Radiotherapy, Intensity-Modulated 3Paclitaxel 3Neoadjuvant Therapy 3Leucovorin 3Dexrazoxane 3Cryosurgery 3

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Terminated × Sarcoma × aflibercept × Clear all
NCT02192541 2018-03-29

Ganetespib and Ziv-Aflibercept in Refractory Gastrointestinal Carcinomas, Non-Squamous Non-Small Cell Lung Carcinomas, Urothelial Carcinomas, and Sarcomas

National Institutes of Health Clinical Center (CC)

Phase 1 Terminated
5 enrolled 15 charts
Sarcoma

Neoplasms, Sarcoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡